UNSPSC 51141596: Phenytoin sodium

This classification denotes a cation channel blocker and anticonvulsant agent with the molecular formula C15H11N2O2.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4182431BJH, chemically known as 5,5-diphenylhydantoin sodium salt but more generally known as diphenylhydantoin sodium, which bears US NIH Compound Identifier 12425. European Medicines Agency schedules Phenytoin sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03787MIG.

Most nations, for tariff and trade purposes, schedule phenytoin sodium under HS 29332100 and SITC 51572. As of Q4 2014, PHENYTOIN SODIUM remains US FDA's Preferred Term for this commodity. Phenytoin sodium bears US NLM identifiers UMLS ID C0237417 and NCI Concept Code C48011. SMILES: C1CCC(CC1)C2(C(=O)[N-]C(=O)N2)C3CCCCC3.[NA+].

UNSPSC 51141596 Phenytoin sodium is a Commodity code that nominally designates a specific anticonvulsant pharmaceutical product, but the recent state and local solicitations tagged under this code show little activity directly aligned with phenytoin procurement. Instead, the opportunities reflect a broader pattern of state and local health agencies, public works departments, and cooperative purchasing alliances procuring pharmaceuticals, over-the-counter products, and related health-system supplies through competitive and cooperative channels. The Seminole County, Florida procurement (IFB 60459723LAS) sought naloxone and drug deactivation systems for community health initiatives, while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP (S1070000015802) established framework contracts for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers to state and local facilities across multiple jurisdictions including Oregon. The issuing bodies span county health departments, regional public-works utilities, state health agencies, and multi-state cooperative purchasing vehicles, with no single repeat buyer dominating recent activity.

Geographic spread across recent opportunities includes Florida (Seminole County), California (Orange County Public Works), Texas (HHS Commission), and Minnesota (MMCAP with Oregon participation). Representative recent solicitations include Seminole County's IFB for naloxone and drug deactivation systems with a July 26, 2023 response deadline, Orange County Public Works' IFB 0803008401RE for sodium hypochlorite and sulfuric acid with a March 27, 2026 deadline and five-year contract term including DVBE and local small-business preference deductions of five to eight percent, and MMCAP's RFP S1070000015802 for generic pharmaceuticals and OTC products due March 26, 2026 with July 1, 2026 contract effectiveness and pricing weighted at seventy-five percent of evaluation. The Texas HHS Commission's RFI HHS0017013 on direct-to-manufacturer prescription programs (April 3, 2026 response date) reflects early-stage market intelligence gathering rather than formal competitive procurement. The code shows mixed recent activity with no dominant procurement pattern directly addressing phenytoin sodium by name.